Phase 2RecruitingNCT06791291
Teplizumab in Japanese stage-2 T1D
Sanofi phase 2 study testing the approved teplizumab delay regimen in Japanese pediatric and adult participants with stage-2 type 1 diabetes.
Primary endpoints
- Progression to stage-3 T1D
- Change from baseline in C-peptide AUC
- Safety and tolerability
Results so far
No results posted yet.